Italy
· Delayed Price · Currency is EUR Farmacosmo Statistics
Total Valuation
Farmacosmo has a market cap or net worth of EUR 27.56 million. The enterprise value is 29.70 million.
| Market Cap | 27.56M |
| Enterprise Value | 29.70M |
Important Dates
The last earnings date was Monday, March 31, 2025.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Farmacosmo has 38.81 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 38.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 3.61% |
| Float | 31.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.40 |
| PB Ratio | 2.22 |
| P/TBV Ratio | 30.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.53 |
| EV / Sales | 0.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -48.84 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.03 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | -10.80 |
| Interest Coverage | -2.44 |
Financial Efficiency
Return on equity (ROE) is -20.62% and return on invested capital (ROIC) is -8.23%.
| Return on Equity (ROE) | -20.62% |
| Return on Assets (ROA) | -4.92% |
| Return on Invested Capital (ROIC) | -8.23% |
| Return on Capital Employed (ROCE) | -19.04% |
| Revenue Per Employee | 801,876 |
| Profits Per Employee | -46,388 |
| Employee Count | 90 |
| Asset Turnover | 2.01 |
| Inventory Turnover | 9.11 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.97% in the last 52 weeks. The beta is 0.38, so Farmacosmo's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -27.97% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 0.69 |
| Relative Strength Index (RSI) | 46.64 |
| Average Volume (20 Days) | 15,385 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Farmacosmo had revenue of EUR 68.16 million and -3.94 million in losses. Loss per share was -0.10.
| Revenue | 68.16M |
| Gross Profit | 726,842 |
| Operating Income | -2.67M |
| Pretax Income | -3.40M |
| Net Income | -3.94M |
| EBITDA | -1.15M |
| EBIT | -2.67M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 4.65 million in cash and 6.57 million in debt, giving a net cash position of -1.92 million or -0.05 per share.
| Cash & Cash Equivalents | 4.65M |
| Total Debt | 6.57M |
| Net Cash | -1.92M |
| Net Cash Per Share | -0.05 |
| Equity (Book Value) | 12.63M |
| Book Value Per Share | 0.32 |
| Working Capital | 516,202 |
Cash Flow
In the last 12 months, operating cash flow was -552,873 and capital expenditures -55,309, giving a free cash flow of -608,182.
| Operating Cash Flow | -552,873 |
| Capital Expenditures | -55,309 |
| Free Cash Flow | -608,182 |
| FCF Per Share | -0.02 |
Margins
Gross margin is 1.07%, with operating and profit margins of -3.92% and -5.78%.
| Gross Margin | 1.07% |
| Operating Margin | -3.92% |
| Pretax Margin | -4.99% |
| Profit Margin | -5.78% |
| EBITDA Margin | -1.69% |
| EBIT Margin | -3.92% |
| FCF Margin | n/a |
Dividends & Yields
Farmacosmo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -14.31% |
| FCF Yield | -2.21% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Farmacosmo has an Altman Z-Score of 2.53. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.53 |
| Piotroski F-Score | n/a |